Literature DB >> 21599514

Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.

Michael Mulligan1, Alin Chirindel, Michael Karchevsky.   

Abstract

OBJECTIVES: To determine if FDG PET/CT scans can be used to discriminate between old and new pathologic spine fractures in myeloma patients and also to determine if there is any combination of PET/CT and MR imaging findings that may indicate an impending spine fracture.
MATERIALS AND METHODS: Retrospective review, after IRB approval, by two musculoskeletal radiologists and one nuclear medicine physician was done. PET/CT database was searched to identify studies performed in myeloma patients, using the search terms myeloma, plasmacytoma, or plasma cell. Records, for this group of 176 patients, were searched for concurrent spine MR imaging and report of fracture. The SUV(max) was recorded for each vertebral level from C2 through L5. All other imaging studies carried out in each patient (spine radiographs, spine CTs, and spine MRIs) and clinical records also were reviewed. Spine fractures were identified using the Genant system. MR imaging findings noted included signal intensity, pattern of involvement, as well as the size and location, within the vertebral body, of individual focal lesions.
RESULTS: 31 of the 176 patients had concurrent spine MR imaging and report of fracture. Five of these 31 patients were excluded because they had no documentation of the age of fracture prior to PET/CT imaging. The 26 remaining patients (598 vertebral levels) included 17 men and 9 women. There were a total of 59 PET/CTs, 104 spine X-ray studies, 25 spine CT exams, and 71 spine MRI exams. There were a total of 134 vertebral body fractures: 27 were determined to be acute/subacute and pathologic due to active myeloma, 1 was determined to be new but owing to simple osteoporosis, and 106 were determined to be old. The mean SUV(max) in the acute/subacute pathologic fractures was 2.9 with a range from 1.1 to 4.3 (standard deviation 0.98). The old fractures had a mean SUV(max) of 1.6 with a range from 0.6 to 3.1 (standard deviation 0.55). This was a statistically significant difference with p value <.0001. The 464 vertebral bodies without fracture had a mean SUV(max) of 1.8. SUV(max) ≥2.5 was seen at 49 vertebral levels, including 27 with a fracture and 22 without a fracture. SUV(max) ≥3.5 was found at 9 vertebral levels, including 6 with a fracture and 3 without a fracture. The combination of diffuse or multifocal MR patterns and SUV > 3.5 was seen at 7 levels, all but one with new pathologic fractures.
CONCLUSION: PET/CT SUV > 3.2 alone can be used in myeloma patients to discriminate between old and new pathologic fractures, just as it has been reported in other types of cancer patients. The combination of PET/CT SUV > 3.5 and MR findings of diffuse or multifocal vertebral body involvement seems to indicate an impending fracture.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21599514     DOI: 10.3109/07357907.2011.584589

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  8 in total

Review 1.  The Critical Role of Imaging in the Management of Multiple Myeloma.

Authors:  Shahzad Raza; Siyang Leng; Suzanne Lentzsch
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Plasmacytoma of the Cervical Spine: A Case Study.

Authors:  Richard Pashayan; Wesley M Cavanaugh; Chad D Warshel; David R Payne
Journal:  J Chiropr Med       Date:  2017-03-02

Review 3.  Reconstruction of multiple myeloma lesions around the pelvis and acetabulum.

Authors:  Vasileios I Sakellariou; Andreas F Mavrogenis; Olga Savvidou; Franklin H Sim; Panayiotis J Papagelopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-10-19

4.  Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.

Authors:  Yannick Silva; Jean-Marc Riedinger; Marie-Lorraine Chrétien; Denis Caillot; Jill Corre; Kévin Guillen; Alexandre Cochet; Claire Tabouret-Viaud; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-10

5.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

Review 6.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

7.  Bone cement augmentation procedures for spinal pathologic fractures by multiple myeloma.

Authors:  Kee-Yong Ha; Chang-Ki Min; Jun-Yeong Seo; Young-Hoon Kim; Joo-Hyun Ahn; Nak-Min Hyun; Yoon-Chung Kim
Journal:  J Korean Med Sci       Date:  2014-12-23       Impact factor: 2.153

8.  Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study.

Authors:  D Anitha; Thomas Baum; Jan S Kirschke; Karupppasamy Subburaj
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.